Efficacy and safety of granisetron (Kytril) in two special patient populations: children and adults with impaired hepatic function.
Palmer
R
R
Department of Gastroenterology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406.
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D002746:Chlorpromazine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000627:therapeutic use; D017829:Granisetron / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D017093:Liver Failure / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism* / Q000556:secondary; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D009369:Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000970:Antineoplastic Agents; D002746:Chlorpromazine; D003907:Dexamethasone; D017829:Granisetron